Literature DB >> 9781734

Continuous intravenous terbutaline for pediatric status asthmaticus.

D E Stephanopoulos1, R Monge, K H Schell, P Wyckoff, B M Peterson.   

Abstract

OBJECTIVES: To determine the clinical effects of intravenous terbutaline at >0.4 microg/kg/min in children with status asthmaticus; to describe the clinical findings associated with such therapy, including creatinine phosphokinase-myocardial band isoenzyme (CPK-MB) concentrations, electrocardiographic alterations, and decreased diastolic blood pressure (DBP) with terbutaline usage; and to assess the requirement for epinephrine to counteract the decrease in diastolic blood pressure.
DESIGN: A retrospective review of children admitted with status asthmaticus who failed emergency room therapy and required intravenous terbutaline.
SETTING: San Diego Children's Hospital Pediatric Intensive Care Unit. PATIENTS: Eighteen children with status asthmaticus, based on clinical and laboratory criteria, between September 1994 and July 1996.
INTERVENTIONS: Epinephrine was added for below-normal decreases in diastolic blood pressure.
MEASUREMENTS AND MAIN RESULTS: Continuous monitoring for arrhythmias, ST-segment changes, and DBP values during variations in the dose of intravenous terbutaline, with or without epinephrine. CPK-MB concentrations were determined in 15 of 18 patients.
CONCLUSIONS: Intravenous terbutaline was well tolerated in asthmatic children for < or =305 continuous hours and at varying doses up to a maximum of 10 microg/kg/min. There was no relationship between the magnitude of CPK-MB concentrations and the terbutaline or epinephrine doses used. Arrhythmias were rare and not related to either terbutaline or epinephrine doses. However, ST-segment depression did occur in two patients requiring high-dose epinephrine. Terbutaline significantly lowered DBP when used between 0.4 and 1.0 microg/kg/min, which required epinephrine to be initiated. Epinephrine was not required at terbutaline doses of >2 microg/kg/min. There was no mortality.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781734     DOI: 10.1097/00003246-199810000-00033

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

Review 1.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

Review 2.  Management of acute pediatric asthma.

Authors:  John C Carl; Carolyn M Kercsmar
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

3.  Drug treatment of acute severe asthma in children.

Authors:  Rashmi Ranjan
Journal:  World J Pediatr       Date:  2012-02       Impact factor: 2.764

4.  Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.

Authors:  I Federico Fernandez Nievas; Kanwaljeet J S Anand
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

Review 5.  Drug therapy approaches in the treatment of acute severe asthma in hospitalised children.

Authors:  L K DeNicola; M O Gayle; K V Blake
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  Progress in the management of childhood asthma.

Authors:  Pakit Vichyanond; Rattana Pensrichon; Suruthai Kurasirikul
Journal:  Asia Pac Allergy       Date:  2012-01-31

Review 7.  Contemporary treatment of children with critical and near-fatal asthma.

Authors:  Steven L Shein; Richard H Speicher; José Oliva Proença Filho; Benjamin Gaston; Alexandre T Rotta
Journal:  Rev Bras Ter Intensiva       Date:  2016-06

Review 8.  Emergency presentation and management of acute severe asthma in children.

Authors:  Knut Øymar; Thomas Halvorsen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-09-04       Impact factor: 2.953

Review 9.  Paediatrics: how to manage acute asthma exacerbations.

Authors:  James S Leung
Journal:  Drugs Context       Date:  2021-05-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.